6 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 6 Phase 3, 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 4, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow Antibodies, Monoclonal, Humanized: new trials by email Literature Review of Antibodies, Monoclonal, Humanized trials Research Report on Antibodies, Monoclonal, Humanized
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis MG-K10 Injection (Humanized Monoclonal Antibody), Placebo for MG-K10 - Dermatitis, Atopic | Phase 3 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 180 | 2026-04-17 | 2026-04-20 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody, Nucleoside/nucleotide analogues - Hepatitis B, Chronic | Phase 2 | Unknown | Henlix, Inc | 44 | 2019-12-31 | 2020-10-20 |
| Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2019-10-28 | 2025-09-23 |
| Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 511 | 2012-02-01 | 2016-06-27 |
| Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Reslizumab - Eosinophilic Asthma | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 1052 | 2011-06-01 | 2016-06-06 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 489 | 2011-04-01 | 2021-11-09 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 464 | 2011-03-01 | 2021-11-09 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 315 | 2011-02-01 | 2016-06-06 |
| CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas CHOP, Alemtuzumab, Plasma Samples - Non-Hodgkin's Lymphoma | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 24 | 2004-03-01 | 2017-01-20 |
Pulmonary Eosinophilia (5) · Dermatitis, Atopic (1) · Hepatitis B, Chronic (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Small Cell Lung Carcinoma (1)
Teva Branded Pharmaceutical Products R&D, Inc. (5) · Henlix, Inc (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1) · Shanghai Mabgeek Biotech.Co.Ltd (1)
United States (8) · Argentina (3) · Belgium (3) · Brazil (3) · Canada (3) · Colombia (3) · France (3) · Hungary (3) · Israel (3) · Mexico (3) · Poland (3) · Russia (3) · Sweden (3) · Taiwan (3) · Australia (2)
Anne C Chiang (1) · Cheng-Yuan Peng, MD, PhD (1) · Chia-Yen Dai, MD, PhD (1) · Jia-Horng Kao, MD, PhD (1) · Pierluigi Porcu, MD (1) · Steven H Lin (1)
PMID 25736990, PMID 28159511, PMID 30193936, PMID 30346831, PMID 30964365, PMID 31262379, PMID 31626990, PMID 27018175, PMID 27056586
U10CA180868 (1), U10CA180888 (1)